What is Ocrelizumab?

Category: Prescription Drugs

Most popular types: Ocrevus

false

Ocrelizumab is a type of monoclonal antibody that works by targeting certain types of cells in the immune system that are believed to contribute to the auto-immune destruction of nerve cells seen in multiple sclerosis.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Multiple sclerosis 90 56
Participate in clinical trial 16 19
MS hug (tight chest or torso) 2 7
Lhermitte's sign 1 0

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 2
Mild 21
None 39

Commonly reported side effects and conditions associated with Ocrelizumab

Side effect Patients
Nausea 4
Decreased appetite 2
Fatigue 2
Headaches 2
Tiredness 2
Blurry vision 1

Show all 26 reported side effects

Dosages

Based on patients currently taking Ocrelizumab

Dosage Patients
30 mg every 6 months 36
600 mg every 6 months 23
300 mg every other week 6
300 mg every 6 months 4
1 other every 6 months 3
18,000 mg every 6 months 2
600 mL every 6 months 2
60 mg every 6 months 2
30 mg every 3 months 1
300 mg yearly 1

See all 19 dosages

Why patients stopped taking Ocrelizumab

Multiple reasons could be selected

Reason Patients
Did not seem to work 1
Doctor's advice 1
Expense 1
Other 1
Personal research 1
See all 3 patients who've stopped taking Ocrelizumab

Duration

Currently taking Ocrelizumab

Duration Patients
Less than 1 month 1
1 - 6 months 13
6 months - 1 year 38
1 - 2 years 36
5 - 10 years 2

Stopped taking Ocrelizumab

Duration Patients
Less than 1 month 1
1 - 6 months 1
6 months - 1 year 1
Adherence
Adherence Evaluations
Always 60
Usually 0
Sometimes 0
Never taken as prescribed 2
Burden
Burden Evaluations
Very hard to take 1
Somewhat hard to take 5
A little hard to take 21
Not at all hard to take 35
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 1
< $25 33
Not specified 28

What people switch to and from

Patients started taking Ocrelizumab after stopping:

Treatment Patients
Natalizumab (Tysabri) 18
Dimethyl fumarate (Tecfidera) 17
Glatiramer acetate (Copaxone) 11
Fingolimod (Gilenya) 8
Teriflunomide (Aubagio) 8

Show all 13 treatments patients report switching from

Last updated:

1 patient evaluation for Ocrelizumab

Sep 29, 2017 (Started Sep 25, 2017)

  • Effectiveness
    Slight (for multiple sclerosis)
  • Side effects
    Mild (nausea)
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 30 mg Every 6 months
Advice & Tips: worth any side effects for improved health. Better dead than not take ocrevus

  • 1 helpful mark
Last updated:
Showing 1 of 1 patient evaluation for Ocrelizumab